Intercept Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The momentum continues after CymaBay reported great clinical results on Thursday.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Free Report) – Stock analysts at Leerink Partnrs increased their Q4 2023 earnings per share (EPS) estimates for shares of Intercept Pharmaceuticals in a research report issued to clients and investors on Thursday, August 24th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will earn $0.12 per […]

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Free Report) – Equities research analysts at Zacks Research lowered their Q3 2023 earnings per share estimates for shares of Intercept Pharmaceuticals in a report released on Wednesday, August 16th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will earn ($0.46) per share for the quarter, down […]

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Free Report) – Research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Intercept Pharmaceuticals in a research report issued on Thursday, August 3rd. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will post earnings of $0.28 per share for the quarter. HC Wainwright […]

Such a signal from the EMA does not mean that the medicine is the cause of any reported adverse events. Moderna seeks US FDA authorization for updated COVID vaccine Moderna said on Thursday it has completed a submission to the U.S. Food and Drug Administration seeking authorization for its updated COVID-19 vaccine to target the XBB.1.5 subvariant.